{"nctId":"NCT01149096","briefTitle":"Collection of Bone Marrow From Donors Treated With or Without Filgrastim","startDateStruct":{"date":"2010-06-14","type":"ACTUAL"},"conditions":["Healthy Stem Cell Donor","No Evidence of Disease"],"count":13,"armGroups":[{"label":"Arm I (conventional bone marrow harvest)","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Bone Marrow Donation","Other: Laboratory Biomarker Analysis"]},{"label":"Arm II (filgrastim, bone marrow harvest)","type":"EXPERIMENTAL","interventionNames":["Procedure: Bone Marrow Donation","Biological: Filgrastim","Other: Laboratory Biomarker Analysis"]}],"interventions":[{"name":"Bone Marrow Donation","otherNames":[]},{"name":"Filgrastim","otherNames":["G-CSF","Neupogen","r-metHuG-CSF","Recombinant Methionyl Human Granulocyte Colony Stimulating Factor","rG-CSF","Tevagrastim"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Appropriately human leukocyte antigen (HLA)-matched (HLA, A, B, DRB1 identical or antigen mismatched \\[i.e., 5/6 or 6/6 antigens matched\\]) sibling of the bone marrow recipient enrolled on COG-ASCT0631\n* Adequate size relative to the recipient (i.e., harvesting the maximum of 20 cc/kg from the donor would result in a bone marrow graft that will provide an adequate cell and volume dose to the recipient, in the opinion of the treating physician)\n* Enrolled on the COG Umbrella Long-Term Follow-Up Study COG-ALTE05N1\n* Not pregnant or nursing\n* No human immunodeficiency virus (HIV) positivity\n* No sickle cell trait or sickle cell anemia/disease\n* Not at an increased risk from bone marrow donation after filgrastim administration due to a pre-existing medical condition, as determined by an independent physician separate from the research team\n* None of the following:\n\n  * Active infection, especially pulmonary\n  * Splenomegaly or a history of splenic injury\n  * Active or recent pulmonary disease (i.e., pneumonia within the past 4 weeks)\n  * A condition that would make the donor unsuitable to donate, as determined by an independent physician separate from the research team\n* No autoimmune disease","healthyVolunteers":true,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Short-term Adverse Events in G-CSF (Filgrastim) Stimulated Bone Marrow (G-BM) Donors","description":"The Kaplan-Meier method will be used to estimate the cumulative incidence of short term adverse events defined by having any of the following events: 1) death due to a cause that is unknown or possibly related to G-CSF, 2) development of a malignancy, 3) development of a splenic rupture, or 4) development of a severe acute lung injury possibly related to GCSF therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced Death in G-CSF Stimulated-bone Marrow (G-BM) Donors","description":"The Kaplan-Meier method will be used to estimate the cumulative incidence of death event in G-BM donors only.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Grade 1 or 2 Toxicities","description":"Estimate the percentage of patients having non-fatal complications of CTCAE Grades 1 or 2 in standard BM and G-CSF stimulated-bone marrow (G-BM) donors.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Grade 3 or 4 Toxicities","description":"Estimate the percentage of patients having non-fatal complications of Grade 3 other than pain (consider Grade 4 for pain only), or any of Grade 4 in standard BM and G-CSF stimulated-bone marrow (G-BM) donors. Modified Toxicity Criteria and Pain Assessment was used with higher grades corresponding to more severe AEs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"10-year Mortality Rate in Marrow Donors","description":"The Kaplan-Meier method will be used to estimate overall survival probabilities in standard BM and G-BM donors.","paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"10-year Overall Cancer Incidence","description":"The Kaplan-Meier method will be used to estimate overall cancer free probabilities in standard BM and G-BM donors.","paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"10-year Hematologic Cancer Rate","description":"The Kaplan-Meier method will be used to estimate hematologic cancer probabilities in standard BM and G-BM donors.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Absolute T Cell Numbers","description":"Median and interquartile range of the outcome measure in standard BM and G-BM donors.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Th1 vs. Th2 Profile of T Cells","description":"Proportion of donors with Th1-T cell profile in standard BM and G-BM donors.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Dendritic Cell (DC) Populations","description":"Median and interquartile range of the outcome measure in standard BM and G-BM donors.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"T Regulatory Cell Content","description":"Median and interquartile range of the outcome measure in standard BM and G-BM donors.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Fatigue","Loss of Appetite (Anorexia)","Throat pain","Back pain","Hip pain"]}}}